Trials / Completed
CompletedNCT04578496
A Safety Extension Study in Patients With Erythropoietic Protoporphyria (EPP)
A Phase III, Safety Extension Study in Patients With Erythropoietic Protoporphyria (EPP)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Clinuvel Pharmaceuticals Limited · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The main objectives of the study were to evaluate the safety and tolerability of afamelanotide by measuring treatment emergent adverse events (AEs) and to determine whether afamelanotide can improve the quality of life of EPP patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Afamelanotide |
Timeline
- Start date
- 2011-07-11
- Primary completion
- 2014-02-27
- Completion
- 2014-02-27
- First posted
- 2020-10-08
- Last updated
- 2020-11-19
- Results posted
- 2020-11-02
Source: ClinicalTrials.gov record NCT04578496. Inclusion in this directory is not an endorsement.